Who is sponsoring NCT03543215?

NCT03543215 is sponsored by Imperial College London.

What drugs are being tested in NCT03543215?

Interventions in NCT03543215: Radiomics: Analysis of textural features of imaging (MRI and Ultrasound).

What condition does NCT03543215 study?

NCT03543215 studies Endometrial Cancer, Endometrial Neoplasms.

Is NCT03543215 still recruiting?

NCT03543215 is currently status unknown. Last updated 12 February 2021.

Last reviewed 2021-02-12 · How we verify

NCT03543215

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Can Staging Magnetic Resonance Imaging (MRI) Features Prognosticate Patients Presenting With Endometrial Cancer?

Status unknown Last updated 12 February 2021

What this trial tests

trial testing Radiomics: Analysis of textural features of imaging (MRI and Ultrasound) in Endometrial Cancer in 500 participants. Status unknown.

Timeline

13 July 2017

Primary endpoint
10 December 2021

10 December 2025

Quick facts

Lead sponsor	Imperial College London
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	13 July 2017
Primary completion	10 December 2021
Estimated completion	10 December 2025
Sites	1 location across United Kingdom

Drugs / interventions tested

Radiomics: Analysis of textural features of imaging (MRI and Ultrasound)

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →
Endometrial Neoplasms — all drugs for Endometrial Neoplasms →

Sponsor

Imperial College London

Who can join

18 and older, female only, with Endometrial Cancer or Endometrial Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim: Assess the value of MRI features in predicting prognosis in patients with endometrial cancer This study will examine the MRI features of women with confirmed endometrial cancer to see if textural features can prognosticate patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Prediction of Deep Myometrial Infiltration, Clinical Risk Category, Histological Type, and Lymphovascular Space Invasion in Women with Endometrial Cancer Based on Clinical and T2-Weighted MRI Radiomic Features.
Li X, Dessi M, Marcus D, Russell J, et al · · 2023 · cited 16× · PMID 37190137 · DOI 10.3390/cancers15082209
An Integrated Clinical-MR Radiomics Model to Estimate Survival Time in Patients With Endometrial Cancer.
Li X, Marcus D, Russell J, Aboagye EO, et al · · 2023 · cited 14× · PMID 36484309 · DOI 10.1002/jmri.28544
Weibull parametric model for survival analysis in women with endometrial cancer using clinical and T2-weighted MRI radiomic features.
Li X, Marcus D, Russell J, Aboagye EO, et al · · 2024 · cited 5× · PMID 38724889 · DOI 10.1186/s12874-024-02234-1

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03543215 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 12 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03543215.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing